GlassScriptPhysician profile
George C Fareed
NPI 1720074313
$7,389.08
in general payments reported to CMS, 2019-2025
46 companies · $1,222 in 2025
The $1,222 reported for 2025 was more than what 93% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,632 · 2020: $986 · 2021: $519 · 2022: $965 · 2023: $1,211 · 2024: $854 · 2025: $1,222.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,947 · Long Term Medical Supply Or Device Loan: $268 · Education: $72.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,946.89 |
| Long Term Medical Supply Or Device Loan | $267.84 |
| Education | $72.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $1,326.77 | 2019-2025 | Dovato, Cabenuva, Apretude |
| Janssen Biotech, INC. | $1,117.37 | 2019-2023 | Tremfya, Symtuza |
| Janssen Products, LP | $675.64 | 2019-2023 | Symtuza |
| Gilead Sciences, INC. | $548.50 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $409.98 | 2019-2025 | Airsupra, Farxiga |
| Novo Nordisk INC | $394.95 | 2019-2025 | Wegovy, Ozempic |
| Merck Sharp & Dohme LLC | $336.52 | 2019-2025 | Delstrigo, Pifeltro, Dificid |
| Smith+Nephew, INC. | $283.90 | 2019-2024 | Collagenase Santyl |
| Integra Lifesciences Corporation | $267.84 | 2025 | Micromatrix, Cytal |
| Corcept Therapeutics | $204.66 | 2022-2025 | Korlym |
| Supernus Pharmaceuticals, INC. | $162.59 | 2020 | |
| Abbvie INC. | $152.44 | 2019-2023 | |
| Medtronic Minimed, INC. | $136.54 | 2019 | |
| Amgen INC. | $108.95 | 2019-2025 | Prolia, Evenity, Repatha |
| Novartis Pharmaceuticals Corporation | $101.80 | 2019-2023 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Fareed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.